Evidence map›Paper›PMID 7703623›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1995

Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.

R Rizzoli, T Chevalley, D O Slosman, J P Bonjour

Abstract readClinical TrialComparative StudyControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997
    Trial
  3. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1996
    Trial
  4. Article
  5. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002
    Review
  6. Review
  7. Review
  8. Review
  9. Steroid-induced osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

R RizzoliDivision of Clinical Pathophysiology (World Health Organization Collaborating Center for Osteoporosis and Bone Disease), University Hospital of Geneva, Switzerland.
T Chevalley
D O Slosman
J P Bonjour
University Hospital of Geneva · CHWorld Health Organization · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corticosteroid-induced osteoporosis, which particularly affects the axial skeleton and the proximal femur, is characterized by a state of low bone remodelling. Fluoride is a potent stimulator of trabecular bone formation which could potentially be useful in the treatment of corticosteroid-induced osteoporosis. We investigated the effects of sodium monofluorophosphate (26 mg/day of fluoride) combined with 1000 mg of calcium (MFP-calcium-treated group), or of calcium alone (control), given for 18 months, on bone mineral density (BMD) of lumbar spine (LS), femoral neck (FN) and midfemoral shaft (FS) in 48 patients with corticosteroid-induced osteoporosis. Mean ages were 49.4 +/- 3.1 and 51.6 +/- 3.0 years (mean +/- SEM), duration of corticosteroid therapy 7.5 +/- 1.8 and 9.3 +/- 1.7 years, and mean daily dose of prednisone 18.2 +/- 2.3 and 12.1 +/- 1.1 mg in the MFP-calcium-treated group and controls, respectively. Initial BMDs (expressed as the Z-score, i.e. the difference in standard deviations from age- and sex-matched normal subjects) were -1.5 +/- 0.2 and -1.2 +/- 0.2 for LS, -1.4 +/- 0.2 and -1.3 +/- 0.2 for FN, and -0.8 +/- 0.3 and -0.6 +/- 0.3 for FS, in the MFP-calcium-treated group and controls, respectively. Analysis by linear regression of 6-monthly measurement values revealed BMD changes of +7.8 +/- 2.2 versus +3.6 +/- 1.3% (p < 0.02) for LS, -1.5 +/- 1.8 versus +0.9 +/- 1.8% for FN, and -1.1 +/- 1.1 versus -0.5 +/- 1.4% for FS after 18 months of follow-up in the MFP-calcium-treated group and controls, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Indexed as

Adrenal Cortex HormonesAgedBone DensityFemaleFemurFluoridesHumansMaleMiddle AgedOsteoporosisPhosphatesSpineAdrenal Cortex HormonesFluoridesfluorophosphatePhosphates

Identifiers

PMID7703623
OpenAlexW2070676242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.